PSTV Stock Jumps 25% on Rhenium Obisbemeda Hopes

By Jungwook Shin · Updated April 10, 2026

PSTV had a solid session today. Here’s the breakdown on the 25.3% move.

PSTV shares surged 25.3% in today’s session as buyers stepped back into Plus Therapeutics, Inc., though the specific catalyst remains murky with no major news releases or SEC filings hitting the wire. Our comfort level with this move is partial — the absence of a clear fundamental trigger suggests this could be more about technical positioning or sector rotation than a material business development.

The stock has been under significant pressure recently, trading well below its 50-day moving average at $6.19 and sitting near multi-month lows. Today’s move comes as the broader healthcare sector lagged, with XLV down 0.84%, making PSTV’s performance stand out even more. What’s notable here is the timing — with 11.7% of the float short and 4.36 days to cover, this could reflect some combination of short covering and opportunistic buying at technically oversold levels.

The real story today might be less about a specific catalyst and more about value hunters circling a beaten-down biotech with a legitimate radiotherapy pipeline. Worth noting: the stock trades at just 6.34x sales despite having $8.61M in cash and relatively manageable debt at $821K.

What This Company Does

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, focused on developing targeted radiotherapeutics for brain and central nervous system cancers. With a $33.07M market cap and just 28 employees, this is a lean operation centered around their lead radiotherapeutic candidate, rhenium obisbemeda — a patented radiotherapy for patients with recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.

The company also develops Rhenium-188 NanoLiposome technology for solid organ cancers and commercializes laboratory-developed tests including the CNSide Test for identifying tumor cells that have metastasized to the central nervous system. Per Wikipedia, their lead therapeutic candidate is marketed as REYOBIQ™ and is currently under clinical evaluation. The company formerly operated as Cytori Therapeutics before changing its name to Plus Therapeutics in July 2019, reflecting its pivot toward radiopharmaceuticals.

Why It Moved Today

The catalyst picture for today’s 25.3% surge remains unclear, with no major press releases, FDA updates, or material SEC filings driving the move. The most recent [8-K filed April 9th](https://www.sec.gov/Archives/edgar/data/1095981/000119312526148920/pstv-20260408.htm) doesn’t appear to contain market-moving information, suggesting this rally is more technically or sentiment-driven than fundamentally triggered.

What stands out here is the technical setup before today’s move. PSTV had been trading at deeply oversold levels with RSI around 37.52, well below its 50-day moving average, and within the lower half of its Bollinger Bands. The stock appeared priced for bad news, which can create explosive moves higher when short covering meets opportunistic buying. Given the 11.7% short interest and 4.36 days to cover, today’s volume spike could reflect forced covering as technical momentum shifted.

The broader biotech space has been under pressure recently, but individual names with differentiated pipelines have shown sudden revival when institutional buyers see value. According to recent analyst coverage cited by Zacks, Plus Therapeutics reported break-even earnings for Q4, which represents a significant improvement from the massive losses in prior quarters. This earnings stability might be attracting value-focused biotech investors back to the name.

I’d lean cautious here because headline-driven moves without fundamental catalysts tend to fade quickly in small biotech names. However, the technical oversold bounce combined with improved quarterly results creates a more sustainable setup than pure momentum plays.